Huangpu's fiscal expenditure totals 10b yuan in Q1
2021-04-19The fiscal expenditure of Guangzhou's Huangpu district reached 10.07 billion yuan ($1.55 billion) in the first quarter of this year, up 27 percent year-on-year.
Huangpu begins vaccination for foreigners
2021-04-19Lingnan Hospital of the Third Affiliated Hospital of Sun Yat-sen University began providing COVID-19 vaccination to Hong Kong and Macao people and foreigners in Guangzhou's Huangpu district on April 16.
Huangpu eyes 100b-yuan biological innovation industrial cluster
2021-04-16Guangzhou's Huangpu district will foster a biological innovation industrial cluster of more than 100 billion yuan ($15 billion) during the 14th Five-Year Plan Period (2021-25).
WeRide obtains permit for autonomous driving tests in US
2021-04-15The California Department of Motor Vehicles recently issued a permit authorizing Huangpu enterprise WeRide to test autonomous vehicles without safety personnel on public roads in San Jose.
4 business complexes agree to settle in Huangpu
2021-04-15Four iconic business complexes signed agreements to settle in Guangzhou's Huangpu district on April 13.
Huangpu fiscal budget to allocate 1.36b yuan for key projects
2021-04-14Guangzhou's Huangpu district will earmark 1.36 billion yuan ($208.3 million) from its fiscal budget this year to invest in industrial, transport, educational and medical projects.
Guangdong Provincial People's Hospital to branch out in Huangpu
2021-04-14Guangdong Provincial People's Hospital is set to create a new campus in Guangzhou's Huangpu district.
Huangpu offers COVID-19 vaccinations to foreign expats
2021-04-13Foreigners in Guangzhou's Huangpu district can now make reservations for COVID-19 vaccines via WeChat service platform Yue Jian Tong.
Huangpu hosts Guangdong-HK-Macao biomedicine industry conference
2021-04-13The second Guangdong-Hong Kong-Macao Biomedicine and Biomedical Engineering Industry Conference was held in the Guangzhou Development District on April 9 and 10.
BeiGene wins approval for commercial manufacturing of antibody
2021-04-09Chinese biotech company BeiGene Ltd announced on Thursday the approval from the China National Medical Products Administration to begin manufacturing commercial supply of its approved anti-PD-1 antibody.
Links
>
- Investment and Entrepreneurship
- Investment Advantages
- Investment Guide
- Policies
- Key Projects
- Major Industries
- Industrial Parks
- Investment Opportunities
- Technological Innovation
- IPR
- Enterprises
- Talents
Copyright © Guangzhou Development District People's Government.
All rights reserved. Presented by China Daily
粤ICP备16087157号-1
All rights reserved. Presented by China Daily
粤ICP备16087157号-1